Research Analysts Set Expectations for Alkermes Q3 Earnings

Alkermes plc (NASDAQ:ALKS - Free Report) - Research analysts at Zacks Research decreased their Q3 2026 earnings per share estimates for shares of Alkermes in a note issued to investors on Wednesday, April 9th. Zacks Research analyst R. Department now forecasts that the company will post earnings per share of $0.23 for the quarter, down from their prior estimate of $0.24. The consensus estimate for Alkermes' current full-year earnings is $1.31 per share. Zacks Research also issued estimates for Alkermes' Q1 2027 earnings at $0.18 EPS.

Alkermes (NASDAQ:ALKS - Get Free Report) last released its quarterly earnings results on Wednesday, February 12th. The company reported $0.92 EPS for the quarter, topping analysts' consensus estimates of $0.81 by $0.11. Alkermes had a net margin of 23.57% and a return on equity of 30.80%.

A number of other brokerages have also recently weighed in on ALKS. HC Wainwright reissued a "neutral" rating and set a $46.00 price objective on shares of Alkermes in a report on Thursday, February 13th. Royal Bank of Canada started coverage on shares of Alkermes in a report on Thursday, March 13th. They issued a "sector perform" rating and a $40.00 price objective for the company. The Goldman Sachs Group increased their target price on shares of Alkermes from $30.00 to $32.00 and gave the company a "buy" rating in a report on Friday, February 14th. UBS Group raised shares of Alkermes from a "sell" rating to a "neutral" rating and boosted their price target for the stock from $21.00 to $38.00 in a research note on Tuesday, March 4th. Finally, StockNews.com upgraded Alkermes from a "buy" rating to a "strong-buy" rating in a report on Thursday, February 13th. Four analysts have rated the stock with a hold rating, eight have given a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average price target of $38.50.

Remove Ads

Alkermes Stock Performance

ALKS traded down $1.13 during trading on Friday, reaching $26.81. The stock had a trading volume of 948,523 shares, compared to its average volume of 1,751,103. The business has a 50-day moving average of $33.00 and a 200-day moving average of $30.46. Alkermes has a one year low of $22.90 and a one year high of $36.45. The stock has a market cap of $4.42 billion, a PE ratio of 12.35, a PEG ratio of 2.20 and a beta of 0.39.

Insider Transactions at Alkermes

In other Alkermes news, EVP Craig C. Hopkinson sold 100,918 shares of the company's stock in a transaction dated Thursday, January 30th. The shares were sold at an average price of $32.05, for a total value of $3,234,421.90. Following the sale, the executive vice president now owns 44,290 shares in the company, valued at approximately $1,419,494.50. This represents a 69.50 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Corporate insiders own 4.89% of the company's stock.

Institutional Investors Weigh In On Alkermes

A number of hedge funds have recently added to or reduced their stakes in the stock. Natixis Advisors LLC increased its holdings in Alkermes by 36.8% in the 4th quarter. Natixis Advisors LLC now owns 49,922 shares of the company's stock worth $1,436,000 after acquiring an additional 13,432 shares in the last quarter. JPMorgan Chase & Co. boosted its position in shares of Alkermes by 147.4% in the fourth quarter. JPMorgan Chase & Co. now owns 889,472 shares of the company's stock worth $25,581,000 after purchasing an additional 529,962 shares during the period. Sanctuary Advisors LLC increased its stake in shares of Alkermes by 254.5% in the third quarter. Sanctuary Advisors LLC now owns 32,791 shares of the company's stock worth $944,000 after purchasing an additional 23,541 shares in the last quarter. Barclays PLC raised its position in shares of Alkermes by 108.8% during the 3rd quarter. Barclays PLC now owns 423,931 shares of the company's stock valued at $11,867,000 after purchasing an additional 220,893 shares during the period. Finally, Savant Capital LLC lifted its stake in shares of Alkermes by 11.6% during the 4th quarter. Savant Capital LLC now owns 11,075 shares of the company's stock valued at $319,000 after buying an additional 1,152 shares in the last quarter. 95.21% of the stock is currently owned by hedge funds and other institutional investors.

Alkermes Company Profile

Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders.